Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$7.42 USD

7.42
189,582

-0.13 (-1.72%)

Updated Aug 27, 2024 03:59 PM ET

After-Market: $7.40 -0.02 (-0.27%) 7:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.

Why Is AngioDynamics (ANGO) Up 2.3% Since Last Earnings Report?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AngioDynamics (ANGO) Q4 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.

AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.

AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System

by Zacks Equity Research

AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.

AngioDynamics (ANGO) Up 4.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why You Should Hold AngioDynamics (ANGO) in Your Portfolio

by Zacks Equity Research

Investor optimism is high on AngioDynamics (ANGO) stock, courtesy of its solid prospects.

AngioDynamics (ANGO) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q3.

AngioDynamics (ANGO) Soars 7.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

AngioDynamics (ANGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

AngioDynamics (ANGO) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 166.67% and 4.04%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AngioDynamics (ANGO) Q3 Earnings Expected to Decline

by Zacks Equity Research

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics (ANGO) at a 52-Week High: What's Driving It?

by Zacks Equity Research

AngioDynamics (ANGO) is optimistic about NanoKnife platform growth and the recent launch of Auryon Atherectomy.

Cooper Companies (COO) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.

Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veeva Systems' (VEEV) core Subscription business and Professional Service segments perform impressively in fiscal Q4.

    Patterson Companies (PDCO) Q3 Earnings Top Estimates, Up Y/Y

    by Zacks Equity Research

    Patterson Companies' (PDCO) fiscal third-quarter 2021 results benefit from strong segmental performance.

    Hologic (HOLX) Boosts Diagnostics Portfolio With New Buyout

    by Zacks Equity Research

    Hologic (HOLX) strengthens international capabilities and expands diagnostics arm across test menu, customer segments and geography with recent acquisition.

    DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates

    by Zacks Equity Research

    DENTSPLY SIRONA (XRAY) witnesses consumable revenue growth in the fourth quarter.

    PRA Health (PRAH) Stock Down 2.8% Despite Q4 Earnings Beat

    by Zacks Equity Research

    PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.

    Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

    LHC Group (LHCG) Q4 Earnings Beat Estimates, Revenues Miss

    by Zacks Equity Research

    LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health and hospice admissions.

    Allscripts (MDRX) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Allscripts (MRDX) witnessed expansion in gross margin, driven by better-than-expected software revenues and consistent decline in operating expenses.

    Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss

    by Zacks Equity Research

    Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.

    Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.

    Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss

    by Zacks Equity Research

    Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.

    Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.